A sixteen-year-old patient who has been taking puberty blockers for three years and gender-affirming hormones for one is, depending on the state of residence, receiving the standard of care recommended by the major American clinical societies, receiving a treatment that has been criminalized for prescribing physicians, or receiving care under emergency injunctions that may be reversed in the next legislative session. The same clinical decision, the same medication, the same patient profile produces three categorically different regulatory environments depending on geography. The fragmentation has no parallel in any other area of pediatric medicine, and its implications for clinical research, training, and patient outcomes will reshape the field over a longer horizon than the current political moment suggests.
The clinical practice of pediatric gender-affirming care developed over roughly two decades, beginning with the Dutch protocol for adolescent gender dysphoria and extending through clinical guidelines published by the World Professional Association for Transgender Health, the Endocrine Society, and the American Academy of Pediatrics. The standard practice that emerged involved careful psychiatric evaluation, consideration of puberty blockers in early-pubertal adolescents to delay the development of secondary sex characteristics, and gender-affirming hormone therapy in older adolescents whose persistent gender dysphoria warranted intervention. The clinical model treated this as a complex decision requiring multidisciplinary expertise, individualized assessment, and ongoing monitoring.
What the model did not have, by the standards that other areas of pediatric medicine have developed over similar timeframes, was a robust randomized clinical trial evidence base. The fundamental difficulty is that a randomized controlled trial of pediatric hormone therapy for gender dysphoria—with one arm receiving treatment and another receiving placebo or delayed treatment—has been considered ethically problematic by clinicians who treat the condition. The available evidence has come from observational cohort studies, registry data, and follow-up of clinical case series. The resulting evidence base supports the clinical practice in the views of its practitioners; the same evidence base has been characterized as inadequate by clinicians and policymakers who have reviewed it from a more skeptical posture.
The Cass Review in the United Kingdom, published in 2024, concluded that the clinical evidence supporting puberty blockers and gender-affirming hormones in adolescents was weaker than the clinical practice had assumed and recommended substantial caution in pediatric prescribing. The NHS in England subsequently restricted puberty blocker availability outside of clinical trial settings. The Cass Review’s findings have been controversial within the field—some clinicians have argued that the review applied evidence standards more stringent than those used in other areas of pediatric medicine, while others have argued that the review identified genuine gaps that the field needed to address. The review’s influence has extended well beyond the UK; several other European countries have implemented similar restrictions or are reviewing their protocols.
In the United States, the clinical and regulatory situation has fragmented along state lines in ways that have no equivalent in the European context. By late 2024, more than twenty states had enacted legislation restricting or prohibiting gender-affirming care for minors, with penalties ranging from professional discipline to criminal charges for prescribing physicians. The legislation has produced a substantial geographic redistribution of the patient population, with families traveling across state lines to access care, telehealth platforms operating across jurisdictional boundaries, and medical centers in permissive states absorbing increased clinical volume. The resulting clinical environment is one in which the standard of care varies not by clinical evidence but by political geography.
The Supreme Court’s decision in United States v. Skrmetti, argued in December 2024 and decided in 2025, addressed the constitutional question of whether state bans on pediatric gender-affirming care violated equal protection on the basis of sex. The Court’s ruling, which upheld the Tennessee ban, established that states could regulate this category of medical practice without triggering heightened constitutional scrutiny. The decision did not require any state to adopt restrictions but did remove a substantial constitutional check on state legislative action, with the result that the geographic patchwork that had been developing over the previous several years became more entrenched.
What this regulatory environment has produced, beyond the immediate effects on patient access, is a peculiar set of consequences for clinical research and training. Clinical centers in restrictive states have limited or eliminated their pediatric gender clinic programs, with corresponding effects on resident and fellow training in this area of practice. Research protocols that depend on enrollment of pediatric patients have, in some cases, been geographically constrained or discontinued. The longitudinal cohort studies that the field has been depending on for evidence generation have lost some of their study sites, with implications for the statistical power and generalizability of their findings.
There is a parallel set of considerations specific to the pharmaceutical supply chain. The medications used in pediatric gender-affirming care—GnRH agonists like leuprolide and histrelin, estradiol in various formulations, testosterone in various formulations—are not specifically labeled for this indication and are prescribed off-label. The off-label prescribing pathway is, in itself, routine in pediatric medicine—the majority of medications used in children are prescribed off-label because of the historical underrepresentation of pediatric populations in pharmaceutical clinical trials. What is unusual about the gender-affirming care context is the political pressure that has been applied to pharmaceutical companies, pharmacies, and prescribers regarding off-label use that, in any other context, would proceed without external scrutiny. Several pharmaceutical manufacturers have been the subject of state attorney general investigations, congressional inquiries, and various forms of pressure regarding their products’ use in this context.
The clinical question that the broader field has been less willing to engage publicly is whether the standard of care that developed over the past two decades was, in some specific respects, not adequately calibrated to the pediatric population it was applied to. The patient population presenting to gender clinics has changed considerably over the same period—shifting from a predominantly male-assigned-at-birth, early-onset population to a more heterogeneous group with a substantial proportion of female-assigned-at-birth adolescents whose gender dysphoria emerged in adolescence rather than early childhood. Whether the clinical protocols developed for the earlier patient population apply equivalently to the contemporary patient population is a clinical question with substantial implications, and the field has been engaging it with varying degrees of openness depending on the political pressures specific clinicians face.
There is a separate question, harder to discuss without political valence, about the role of psychiatric comorbidity in the contemporary patient population. Several published case series have documented high rates of co-occurring autism spectrum disorders, anxiety disorders, depression, and various other conditions among adolescents presenting with gender dysphoria. Lancet Child & Adolescent Health published a substantial analysis of these patterns in 2022, with implications for clinical assessment that the field has incorporated unevenly. Whether the comorbidity patterns reflect underlying neurodevelopmental factors, the consequences of unaddressed gender dysphoria, or selection effects in clinical referral patterns is genuinely contested, and the answer affects how the clinical assessment process should be structured.
What the pediatric gender-affirming care environment has revealed, more starkly than perhaps any other area of contemporary medicine, is the limit of clinical autonomy in the face of organized political opposition. Other areas of medicine have faced political controversy—abortion provision is the obvious comparator—but few have produced the kind of state-by-state criminalization of standard-of-care prescribing that gender-affirming care has produced. The longer-term implications for medical professionalism, for the relationship between clinical societies and state legislatures, and for the willingness of clinicians to enter fields that have become politically contested are substantial. Whether the political environment will eventually stabilize, whether the clinical evidence base will mature in ways that produce more consensus across the political divide, or whether the geographic fragmentation will persist as a permanent feature of American pediatric medicine is unclear. What is clear is that the clinical and regulatory environment that existed five years ago no longer exists, and the clinicians, patients, and families navigating the current environment are doing so without a stable framework to guide them.
